Sangui Bio Tech International Inc.
EANS-News: Sangui Bio Tech International Inc.
BioTech company Sangui strikes a
positive half year balance
--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------
Financial Figures/Balance Sheet
Witten (euro adhoc) - BioTech company Sangui strikes a positive half year
balance
Revenues grow, additional investments in marketing and sales
Witten, Germany, February 15, 2013 - While daily revenues of the wound
therapeutic Granulox grew continuously, Sangui Biotech saw its revenues from
product sales and royalties increasing quarter by quarter since the distribution
of Granulox started in April 2012. In the first six months of its current
financial year they reached almost USD50,000.
Increasingly, the wound therapeutic Granulox is the main growth driver.
Distribution rights for this product were awarded to SastoMed GmbH by Sangui.
Already, Granulox can build upon high satisfaction with patients, excellent
awareness among professionals as well as a steady increase of order intake. In a
recently published clinical study carried out at the Charles University in
Prague (Czech Republic) a significant reduction of wound size was obtained at 97
percent of patients treated with Granulox. Documentations of scientific radiance
like this one enable SastoMed to present the benefits of Granulox to patients
and medical practitioners in an even more convincing way.
"We note that all tokens lead to the right direction", Sangui Director Hubertus
Schmelz emphasizes. "Granulox business has gained considerable momentum now
which can be derived from the steady increase of incoming orders and revenues.
As for the quarters to come we are looking forward to additional growth in
Germany and abroad, a development which will meet our unchanged support as
shareholders of SastoMed."
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of
which are being traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and
the OTC market of Hamburg-Hannover stock exchanges. Its purpose is to provide
financing and access to the capital markets for the enterprises of the Sangui
group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech
International, Inc.
Further inquiry note:
Dr. Joachim Fleing
Fon: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de
end of announcement euro adhoc
--------------------------------------------------------------------------------
company: Sangui Bio Tech International Inc.
Alfred-Herrhausen-Strasse 44
D-58455 Witten
phone: +49(0)2302 915-200
FAX: +49(0)2302 915-191
mail: info@sangui.de
WWW: http://www.sanguibiotech.com
sector: Biotechnology
ISIN: DE0000906757
indexes:
stockmarkets: free trade: Hamburg, New York
language: English